Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids.


Journal

Die Pharmazie
ISSN: 0031-7144
Titre abrégé: Pharmazie
Pays: Germany
ID NLM: 9800766

Informations de publication

Date de publication:
01 Oct 2024
Historique:
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: ppublish

Résumé

Tapentadol is a unique opioid analgesic due to its dual mechanism of action. Compared to other opioids with a classical mechanism of action, its analgesic potential is not far behind them, and its advantages are: a better safety profile in terms of a lower potential for drug-drug interactions and a lower potential for causing adverse events, and it is safe to use in sensitive populations. Tapentadol in the form of a immediate release formulation is an adequate drug of choice for achieving a pharmacotherapeutic analgesic response in acute pain conditions, while in the form of a extended release formulation it is an adequate pharmacotherapeutic analgesic solution for chronic pain syndromes of various etiology. Due to the specificity of the mechanism of action, tapentadol adequately relieves both pain components - nociceptive and neuropathic, and has an indication area for mixed pain syndrome as well. Based on this, the need for the use of co-analgesics is reduced, and thus the incidence of possible interactions and adverse events is reduced.

Identifiants

pubmed: 39407426
doi: 10.1691/ph.2024.4591
doi:

Substances chimiques

Tapentadol H8A007M585
Analgesics, Opioid 0
Phenols 0
Delayed-Action Preparations 0

Types de publication

Journal Article Review Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-183

Auteurs

D Krtinic (D)

Department for Pharmacology and Toxicology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis, Serbia.

G N Rankovic (GN)

Department for Pharmacology and Toxicology, Faculty of Medicine, University of Nis, Serbia.

A Cvetanovic (A)

Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis, Serbia.

I Conic (I)

Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis, Serbia.

M Todorovic Mitic (MT)

Clinic for Oncology, University Clinical Center Nis, Serbia.

M Radic (M)

Department for Oncology, Faculty of Medicine, University of Nis; Clinic for Oncology, University Clinical Center Nis, Serbia.

A Lucic Prokin (AL)

Department for Neurology, Faculty of Medicine, University of Novi Sad; Clinic for Neurology, University Clinical Center Vojvodina, Novi Sad, Serbia, Serbia.

M Cevrljakovic (M)

Clinic for Oncology, University Clinical Center Nis, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH